Gadolinium-based Contrast Agent Market Growth and Forecasts To 2027 Gadolinium-based Contrast Agent Market - Global In

Gadolinium-based Contrast Agent Market - Global Industry
Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024
Gadolinium (Gd) is found as a rare earth metal, which is tough to extract, and it appears like a
silvery white crystal. It is one of the few metals with ferromagnetic properties at room temperature.
Like most of the rare earth metals, gadolinium forms trivalent ions with fluorescent properties.
Gadolinium is used for shielding in neutron radiography and in nuclear reactor as it absorbs neutrons.
Therefore, applications of the metal are seen in oven, microwave, and other electronic components.
In medical field, it is utilized merely in the form of solution composites for radiological images
enhancement. The gadolinium ions that occur in water soluble salts are toxic to human. But chelated
Gd compounds are less toxic to human body as they are filtered out of the kidneys before the free
ions get released into the tissue. This property of Gd increases its use in the medical field, where it is
used as intravenous drug in diagnostic imaging procedures to enhance the quality of magnetic
resonance angiography (MRA) or magnetic resonance imaging (MRI). The global gadolinium-based
contrast agent market is a fairly matured market and is expected to witness a significant growth in the
near future. The growth of the market is likely to be driven during the forecast period by the rising
prevalence of chronic diseases such as cardiac diseases and cancer.
Request for brochure of this report -
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22862
The global gadolinium-based contrast agent market is segmented on the basis of contrast agent type,
disease indication, end-user, and geography. On the basis of contrast agent type, the market is divided
into linear non-ionic agent, linear ionic, macrocyclic non-ionic, and macrocyclic ionic. The rates of
dissociation of Gd from macrocyclic ligands are slower than the dissociation from linear ligands. Higher
the dissociation constant, there is more possibility of de-chelating and release of free Gd ions into the
body which may lead to serious adverse events. Therefore, linear gadolinium-based contrast agents
are widely preferred for MRI scans.
On the basis of disease indication, the market is segmented into cardiovascular disorders, neurological
disorders, respiratory diseases, nephrological disorders, and others. The cardiovascular disorders
segment accounted for a large share of the global market and the trend is expected to continue during
the forecast period. Advancements in cardiac MRI procedures in catheterization labs and promising
reimbursement scenario for contrast agent products used during cardiovascular diagnosis along with
highly developed health care infrastructure in countries such as Germany, the U.K., the U.S., and
Canada are factors fueling the growth of the cardiovascular disorders segment. According to a survey
of the Centers for Disease Control and Prevention, every year about 735,000 people have a heart
attack in the U.S. Out of this number, 525,000 are the first heart attacks and 210,000 happen in people
who have already suffered a heart attack. In addition, growth of the segment is attributed to the rise in
number of diagnostic procedures coupled with the increase in disease burden in developing countries.
In terms of end-user, the market is segmented into hospitals, specialty clinics, diagnostic centers, and
others.